Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.
This potential treatment was added to our pipeline in 2015 and is currently undergoing important experiments. These tests will help us better understand its pharmacokinetics and allow us to determine a prudent dosing strategy in efficacy testing.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
Please give to ALS TDI to help us get promising treatments out of our lab and into people living with ALS.
November 28 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.